Biocon Share Price
Sector: Biotechnology & Drugs
350.55 -1.05 (-0.30%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
349.55
Today’s High
356.95
52 Week Low
290.80
52 Week High
404.60
350.50 -0.90 (-0.26%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
349.45
Today’s High
357.00
52 Week Low
291.00
52 Week High
404.70
Key Metrics
- Market Cap (In Cr) 47021.05
- Beta 0.85
- Div. Yield (%) 0.14
- P/B 1.95
- TTM P/E 40.34
- Peg Ratio 2.6
- Sector P/E 46.46
- D/E 0.01
- Open Price 353.1
- Prev Close 351.6
Biocon Analysis
Price Analysis
-
1 Week2.75%
-
3 Months0.89%
-
6 Month2%
-
YTD-3.82%
-
1 Year3.58%
Risk Meter
- 37% Low risk
- 37% Moderate risk
- 37% Balanced Risk
- 37% High risk
- 37% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 6
- 5
- 5
- 5
- Buy
- 4
- 4
- 4
- 4
- Hold
- 3
- 3
- 3
- 3
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 16
- 15
- 15
- 15
Biocon News
Stocks to watch: TCS, Infosys, HAL, BEL, ONGC among shares in focus today
1 min read . 23 Jun 2025Ozempic, a patent challenge, and $25 bn race for India’s weight-loss drug market
10 min read . 19 Jun 2025Biocon Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 15261.7
- Selling/ General/ Admin Expenses Total
- 3144.4
- Depreciation/ Amortization
- 1687
- Other Operating Expenses Total
- 3753.5
- Total Operating Expense
- 13685.9
- Operating Income
- 1575.8
- Net Income Before Taxes
- 1886.6
- Net Income
- 1013.3
- Diluted Normalized EPS
- 7.85
- Period
- 2025
- Total Assets
- 58797.3
- Total Liabilities
- 37153.3
- Total Equity
- 21644
- Tangible Book Valueper Share Common Eq
- -45.09
- Period
- 2025
- Cashfrom Operating Activities
- 4061.2
- Cashfrom Investing Activities
- -234.1
- Cashfrom Financing Activities
- -1854
- Net Changein Cash
- 2004.3
- Period
- 2024
- Total Revenue
- 14755.7
- Selling/ General/ Admin Expenses Total
- 5341.8
- Depreciation/ Amortization
- 1568.8
- Other Operating Expenses Total
- -29.9
- Total Operating Expense
- 12878.6
- Operating Income
- 1877.1
- Net Income Before Taxes
- 1525.2
- Net Income
- 1022.5
- Diluted Normalized EPS
- 7.89
- Period
- 2024
- Total Assets
- 56070.7
- Total Liabilities
- 36287
- Total Equity
- 19783.7
- Tangible Book Valueper Share Common Eq
- -57.27
- Period
- 2024
- Cashfrom Operating Activities
- 2953.9
- Cashfrom Investing Activities
- -1004.5
- Cashfrom Financing Activities
- -2332.7
- Net Changein Cash
- -380.4
- Period
- 2023
- Total Revenue
- 11174.2
- Selling/ General/ Admin Expenses Total
- 3820.3
- Depreciation/ Amortization
- 1113.1
- Other Operating Expenses Total
- -348.9
- Total Operating Expense
- 9622.5
- Operating Income
- 1551.7
- Net Income Before Taxes
- 897.1
- Net Income
- 462.7
- Diluted Normalized EPS
- 4.35
- Period
- 2023
- Total Assets
- 52042.8
- Total Liabilities
- 34175.9
- Total Equity
- 17866.9
- Tangible Book Valueper Share Common Eq
- -73.26
- Period
- 2023
- Cashfrom Operating Activities
- 1852.5
- Cashfrom Investing Activities
- -14281.8
- Cashfrom Financing Activities
- 13048.7
- Net Changein Cash
- 641.1
- Period
- 2022
- Total Revenue
- 8184
- Selling/ General/ Admin Expenses Total
- 2920.9
- Depreciation/ Amortization
- 814.2
- Other Operating Expenses Total
- -445.1
- Total Operating Expense
- 7079.5
- Operating Income
- 1104.5
- Net Income Before Taxes
- 983.1
- Net Income
- 648.4
- Diluted Normalized EPS
- 5.97
- Period
- 2022
- Total Assets
- 20394
- Total Liabilities
- 11961.5
- Total Equity
- 8432.5
- Tangible Book Valueper Share Common Eq
- 59.28
- Period
- 2022
- Cashfrom Operating Activities
- 1210.4
- Cashfrom Investing Activities
- -1699.1
- Cashfrom Financing Activities
- 242.1
- Net Changein Cash
- -243.3
- Period
- 2021
- Total Revenue
- 7143.1
- Selling/ General/ Admin Expenses Total
- 2762.8
- Depreciation/ Amortization
- 715.1
- Other Operating Expenses Total
- -326.6
- Total Operating Expense
- 6025.8
- Operating Income
- 1117.3
- Net Income Before Taxes
- 1067.7
- Net Income
- 740.5
- Diluted Normalized EPS
- 5.1
- Period
- 2021
- Total Assets
- 18522.3
- Total Liabilities
- 10895.4
- Total Equity
- 7626.9
- Tangible Book Valueper Share Common Eq
- 53.56
- Period
- 2021
- Cashfrom Operating Activities
- 1125.9
- Cashfrom Investing Activities
- -3624.7
- Cashfrom Financing Activities
- 2564
- Net Changein Cash
- 72.3
- Period
- 2020
- Total Revenue
- 6300.5
- Selling/ General/ Admin Expenses Total
- 2352.4
- Depreciation/ Amortization
- 552.2
- Other Operating Expenses Total
- -326.4
- Total Operating Expense
- 5180.8
- Operating Income
- 1119.7
- Net Income Before Taxes
- 1214.9
- Net Income
- 748.2
- Diluted Normalized EPS
- 6.13
- Period
- 2020
- Total Assets
- 14443.8
- Total Liabilities
- 7738
- Total Equity
- 6705.8
- Tangible Book Valueper Share Common Eq
- 46.97
- Period
- 2020
- Cashfrom Operating Activities
- 1283.1
- Cashfrom Investing Activities
- -1558.9
- Cashfrom Financing Activities
- 387.6
- Net Changein Cash
- 165.4
- Period
- 2025-03-31
- Total Revenue
- 4417
- Selling/ General/ Admin Expenses Total
- 811.1
- Depreciation/ Amortization
- 436.3
- Other Operating Expenses Total
- 1054.8
- Total Operating Expense
- 3754.7
- Operating Income
- 662.3
- Net Income Before Taxes
- 486.8
- Net Income
- 344.5
- Diluted Normalized EPS
- 2.71
- Period
- 2025-03-31
- Total Assets
- 58797.3
- Total Liabilities
- 37153.3
- Total Equity
- 21644
- Tangible Book Valueper Share Common Eq
- -45.09
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 4061.2
- Cashfrom Investing Activities
- -234.1
- Cashfrom Financing Activities
- -1854
- Net Changein Cash
- 2004.3
- Period
- 2024-12-31
- Total Revenue
- 3821.4
- Selling/ General/ Admin Expenses Total
- 788.3
- Depreciation/ Amortization
- 425.4
- Other Operating Expenses Total
- 922
- Total Operating Expense
- 3476.9
- Operating Income
- 344.5
- Net Income Before Taxes
- 155.9
- Net Income
- 25.1
- Diluted Normalized EPS
- 0.13
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3590.4
- Selling/ General/ Admin Expenses Total
- 789.6
- Depreciation/ Amortization
- 419.9
- Other Operating Expenses Total
- 932.8
- Total Operating Expense
- 3298.9
- Operating Income
- 291.5
- Net Income Before Taxes
- 98.4
- Net Income
- -16
- Diluted Normalized EPS
- -0.27
- Period
- 2024-09-30
- Total Assets
- 57127.9
- Total Liabilities
- 36134.7
- Total Equity
- 20993.2
- Tangible Book Valueper Share Common Eq
- -47.47
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 705.4
- Cashfrom Investing Activities
- 966.2
- Cashfrom Financing Activities
- -1278.6
- Net Changein Cash
- 403.1
- Period
- 2024-06-30
- Total Revenue
- 3432.9
- Selling/ General/ Admin Expenses Total
- 755.4
- Depreciation/ Amortization
- 405.4
- Other Operating Expenses Total
- 874.4
- Total Operating Expense
- 3185.9
- Operating Income
- 247
- Net Income Before Taxes
- 1145.5
- Net Income
- 659.7
- Diluted Normalized EPS
- 5.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3917.1
- Selling/ General/ Admin Expenses Total
- 741.6
- Depreciation/ Amortization
- 407
- Other Operating Expenses Total
- 930.1
- Total Operating Expense
- 3417
- Operating Income
- 500.1
- Net Income Before Taxes
- 319
- Net Income
- 135.5
- Diluted Normalized EPS
- 1.18
- Period
- 2024-03-31
- Total Assets
- 56070.7
- Total Liabilities
- 36287
- Total Equity
- 19783.7
- Tangible Book Valueper Share Common Eq
- -57.27
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2953.9
- Cashfrom Investing Activities
- -1004.5
- Cashfrom Financing Activities
- -2332.7
- Net Changein Cash
- -380.4
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Biocon Technical
Moving Average
SMA
- 5 Day348.67
- 10 Day351.53
- 20 Day343.4
- 50 Day336.06
- 100 Day338.92
- 300 Day347.79
Biocon Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Glaxosmithkline Pharmaceutical
- 3277.65
- 14.8
- 0.45
- 3515.95
- 1924.3
- 55537.29
- Glenmark Pharmaceuticals
- 1727.95
- 12.05
- 0.7
- 1830.05
- 1199.95
- 48873.98
- Biocon
- 350.55
- -1.05
- -0.3
- 404.6
- 290.8
- 47021.05
- Suven Pharmaceuticals
- 998.8
- 18.8
- 1.92
- 1359
- 696.55
- 38057.41
- Laurus Labs
- 681.45
- 11.7
- 1.75
- 684.6
- 390.3
- 36763.83
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Glaxosmithkline Pharmaceutical
- 59.19
- 28.03
- 29.26
- 16.77
- Glenmark Pharmaceuticals
- 35.81
- 5.37
- 2.17
- 1.82
- Biocon
- 44.49
- 1.94
- 5.73
- 8.83
- Suven Pharmaceuticals
- 94.3
- 14.79
- 23.09
- 30.28
- Laurus Labs
- 114.12
- 8.07
- 18.12
- 11.88
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 08-May-25
- Audited Results & Final Dividend
- 23-Apr-25
- Others
- 04-Apr-25
- To consider Fund Raising
- 30-Jan-25
- Quarterly Results & Others
- 27-Jan-25
- Others
- 30-Oct-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 16-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-25
- 08-May-25
- AGM
- 06-Jun-25
- 05-May-25
- POM
- 02-Apr-25
- 27-Feb-25
- POM
- 24-Sept-24
- 23-Aug-24
- POM
- 09-Aug-24
- 16-May-24
- AGM
- 30-Nov-23
- 27-Oct-23
- POM
- 11-Aug-23
- 23-May-23
- AGM
- 24-Jul-23
- 20-Jun-23
- POM
- 28-Jul-22
- 29-Apr-22
- AGM
- 23-Jul-21
- 28-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 08-May-25
- 04-Jul-25
- 04-Jul-25
- 0.5
- 16-May-24
- 05-Jul-24
- 05-Jul-24
- 0.5
- 24-May-23
- 07-Jul-23
- 07-Jul-23
- 1.5
- 28-Apr-22
- 01-Jul-22
- 30-Jun-22
- 0.5


